CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $526,569 | +87369.9% | 11,601 | +8.1% | 0.09% | +71.7% |
| Q2 2023 | $602 | +20.9% | 10,731 | -2.6% | 0.05% | +29.3% |
| Q1 2023 | $498 | -100.0% | 11,014 | +94.6% | 0.04% | +105.0% |
| Q4 2022 | $230,119,650 | +44933.2% | 5,661 | -27.6% | 0.02% | -60.0% |
| Q3 2022 | $511,000 | +26.2% | 7,821 | +17.3% | 0.05% | +22.0% |
| Q2 2022 | $405,000 | +46.2% | 6,668 | +166.1% | 0.04% | +32.3% |
| Q3 2021 | $277,000 | -8.6% | 2,506 | +2.2% | 0.03% | -27.9% |
| Q2 2021 | $303,000 | +21.2% | 2,452 | +53.4% | 0.04% | +22.9% |
| Q4 2020 | $250,000 | – | 1,598 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |